Semaglutide
Metabolic
A GLP-1 receptor agonist originally developed for type 2 diabetes management. Widely used for weight management through appetite suppression and metabolic regulation.
Community
Reported Adverse Effects
No adverse effects reported yet
Community Consensus
No consensus claims yet — be the first to contribute
Literature
3studies linked · all open in new tab
Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)
Garvey WT, Batterham RL, Bhatta M, et al.
Weight loss with semaglutide 2.4mg was sustained over 2 years.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, et al.
2.4mg weekly semaglutide resulted in 14.9% mean body weight reduction (STEP 1 trial).
Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2)
Davies MJ, Bergenstal R, Bode B, et al.
Semaglutide 2.4mg achieved 9.6% weight loss vs 3.4% with placebo in T2D patients.
Discussion
No discussion yet — be the first to share your experience